What Accent Therapeutics’ AACR 2026 ATX-295 update reveals about the next wave of precision oncology targets
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.
What Certis Oncology Intelligence reveals about the next phase of AI in cancer R&D
Certis Oncology has launched a new AI platform for translational oncology. Read what it could change for cancer drug development.
Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Can ultrasensitive ctDNA monitoring reshape how clinicians track neoadjuvant breast cancer therapy response?
New PREDICT-DNA data suggests ultrasensitive ctDNA monitoring may outperform traditional markers in breast cancer relapse prediction. Read the full analysis.
How Adela’s tissue-free ctDNA methylation test could reshape monitoring of immunotherapy outcomes
Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.
Why Project Santa Fe Foundation and Virchow Medical are testing a proactive future for oncology diagnostics
Project Santa Fe Foundation and Virchow Medical are redefining oncology diagnostics through proactive analytics. Find out what this changes for labs and clinicians.
How the Prostate Cancer Foundation’s $6.3m bet on young investigators could shape the next decade of prostate cancer innovation
Discover why the Prostate Cancer Foundation’s $6.3 million investment in young researchers could shape the future of prostate cancer diagnostics and treatment.
Guardant Health and Merck sign global deal to co-develop cancer companion diagnostics
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
XenoTherapeutics’ takeover of Repare wins near-unanimous vote: What’s at stake for the pipeline
Repare shareholders approve XenoTherapeutics deal. Find out how this nonprofit acquisition could reshape oncology pipeline models.
Pierre Fabre and Iktos partner on AI-designed small-molecule cancer therapies
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.